MD安德森的吉姆·艾利森时代最有影响力100人的一个名为

免疫检查点封锁癌症的发明者，使久负盛名的年度名单

MD安德森新闻Release April 20, 2017

德州MD安德森癌症中心主持的大学免疫学吉姆·艾利森博士，通过治疗免疫系统而不是肿瘤复兴的癌症免疫疗法，其关键洞察力攻击癌症，已被任命为2017年时间100。他的方法推出来治疗这些疾病的一种全新的方式，提高患者的治疗效果和转化癌症研究的过程。乐动体育LDsports中国

名单，现在在它的第14年，认识到世界上最有影响力的个人。随着时间的编辑，主编南茜吉布斯曾表示，名单中：“每年我们这个时代的100强名单让我们退后一步，衡量打动我们的势力......。这种或那种方式，他们各自体现了一个突破：他们打破规则，打破了世界纪录，打破了沉默，打破界限，揭示了什么，我们是有能力的”

佳佳的突破，他从基础科学研究而产生，释放免疫系统找到并消灭癌细胞 - 所谓的免疫检查点封锁的做法。乐动体育LDsports中国这个新的类药物是挽救患者显著数字生活的各种晚期癌症。

“我很感激时间确认为癌症治疗的一个新的支柱免疫治疗的重要性日益增加，”阿利森，谁也的执行董事免疫治疗平台在MD安德森。“我们在成功的癌症免疫治疗的初期。我们的下一步是扩展这些治疗惠及更多患者，我们的平台是强烈的重点是使之成为现实。”

MD安德森的免疫分析平台的血样和肿瘤活检过程中和治疗后，以更好地了解响应和抗治疗前拍摄。该平台是该机构的一部分登月计划^TM值, which is designed to harness scientific knowledge and develop new technologies that will dramatically reduce cancer deaths through prevention, early detection and treatment.

Basic science built immune checkpoint blockade

“We’re pleased to see the impact of Jim’s research accomplishments highlighted alongside those of other great pioneers and icons, and to have a second researcher on the TIME 100 list,” said MD Anderson Ad Interim President Marshall Hicks, M.D. “We’re delighted to have Jim leading our platform efforts, which are crucial to our Moon Shots Program and MD Anderson’s ability to advance progress in this exciting field.”

Allison’s curiosity-driven research, funded in early days by the National Institutes of Health, led to a life-saving treatment approved for six late-stage cancers and in hundreds of clinical trials for additional cancers and earlier stages of disease.

“It is important to note that immune checkpoint blockade came from understanding the basic science of the immune system,” Allison said. “I didn’t set out as a young scientist to develop cancer therapies, but to understand T cells, these amazing cells that travel our bodies to protect us from disease.”

Allison’s research in T cells – the immune system’s targeted weapons against viruses, bacteria and abnormal cells – began during his first stay at MD Anderson in the 1970s and ‘80s, extending to other institutions before Allison returned to MD Anderson in 2012 to establish the platform.

He was co-discoverer of the function of a protein on T cells that acts as a brake, shutting down immune response. His pivotal idea was to block the brake on the T cell, called CTLA4, with an antibody, unleashing the T cells to attack. After demonstrating this approach in mouse models of human cancer, Allison advocated taking the approach to human clinical trials, which led to the development of ipilimumab, known commercially as Yervoy.

易普利姆玛的领路人

Yervoy was approved for advanced melanoma by the U.S. Food and Drug Administration in 2011, after it became the first drug ever shown in a clinical trial to extend the lives of people with metastatic melanoma. Follow-up studies showed that 22 percent of patients treated with the drug in clinical trials survived 10 years or longer, unprecedented results for the disease.

After Allison’s research and the development of ipilimumab created the field of checkpoint blockade, other drugs were developed to block another brake on T cells called PD1, which have been approved for melanoma, Hodgkin lymphoma, and lung, kidney, bladder and head and neck cancers.

“The next challenge is to understand who benefits from treatment, who doesn’t, and develop rational combination therapies to help those who don’t,” Allison said. “There are many possible combinations – with other immunotherapies, targeted therapies, chemotherapies, radiation – and basic science will be important to help us more efficiently sort out these options.”

埃里森持有的免疫维维安大号史密斯特聘讲座，是派克研究所的癌症免疫治疗在MD安德森的主管。

佳佳已经赢得了多项荣誉，近年来，包括2015年拉斯克临床医学研究奖，2014年突破奖，生命科学和2013年AACR-癌症研究所劳埃德·J·奥尔德奖癌症免疫。乐动体育LDsports中国他的美国国家科学院，国家医学科学院，美国癌症研究协会院士，美国微生物科学院，美国科学促进会和美国文理科学院的资深成员。乐动体育LDsports中国

淋巴瘤和黑素瘤拉里·夸克，医学博士，博士，前MD安德森椅子也榜上有名，2010年为他的癌症疫苗研究。乐动体育LDsports中国